Denise L Doolan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1127280/publications.pdf

Version: 2024-02-01

153 papers	9,158 citations	57758 44 h-index	46799 89 g-index
159 all docs	159 docs citations	159 times ranked	8068 citing authors

#	Article	IF	Citations
1	Proteomic identification of the contents of small extracellular vesicles from in vivo Plasmodium yoelii infection. International Journal for Parasitology, 2022, 52, 35-45.	3.1	6
2	Estimating the global burden of Epsteinâ€“Barr virus-related cancers. Journal of Cancer Research and Clinical Oncology, 2022, 148, 31-46.	2.5	84
3	CD161 expression defines new human Î³Î´ T cell subsets. Immunity and Ageing, 2022, 19, 11.	4.2	3
4	A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. Journal of Infectious Diseases, 2021, 223, 10-14.	4.0	21
5	Memory CD8⁺ T cell compartment associated with delayed onset of Plasmodium falciparum infection and better parasite control in sickleâ€cell trait children. Clinical and Translational Immunology, 2021, 10, e1265.	3.8	1
6	Robust correlations across six SARSâ€CoVâ€2 serology assays detecting distinct antibody features. Clinical and Translational Immunology, 2021, 10, e1258.	3.8	28
7	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Reports Medicine, 2021, 2, 100208.	6.5	115
8	Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nature Communications, 2021, 12, 2037.	12.8	125
9	CD8+ TÂcells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity, 2021, 54, 1066-1082.e5.	14.3	106
10	Identification of the Glycan Binding Profile of Human and Rodent Plasmodium Sporozoites. ACS Infectious Diseases, 2021, 7, 2383-2389.	3.8	2
11	Immunomics-guided discovery of serum and urine antibodies for diagnosing urogenital schistosomiasis: a biomarker identification study. Lancet Microbe, The, 2021, 2, e617-e626.	7.3	14
12	Identifying Epstein-Barr virus peptide sequences associated with differential IgG antibody response. International Journal of Infectious Diseases, 2021, 114, 65-71.	3.3	0
13	Malaria research in Australia: looking through the lens of the past towards the future. International Journal for Parasitology, 2021, 51, 1255-1263.	3.1	2
14	Editorial: Coronavirus Disease (COVID-19): Pathophysiology, Epidemiology, Clinical Management and Public Health Response. Frontiers in Public Health, 2021, 9, 807159.	2.7	2
15	A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine, 2021, 74, 103729.	6.1	29
16	Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma. Scientific Reports, 2021, 11, 23664.	3.3	4
17	Evaluation of the antibody response to the EBV proteome in EBVâ€associated classical Hodgkin lymphoma. International Journal of Cancer, 2020, 147, 608-618.	5.1	15
18	Deciphering host immunity to malaria using systems immunology. Immunological Reviews, 2020, 293, 115-143.	6.0	13

#	Article	IF	Citations
19	Suboptimal SARS-CoV-2â"specific CD8 ⁺ T cell response associated with the prominent HLA-A*02:01 phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24384-24391.	7.1	168
20	A population of CD4 hi CD38 hi T cells correlates with disease severity in patients with acute malaria. Clinical and Translational Immunology, 2020, 9, e1209.	3.8	3
21	Chimeric Virus-Like Particles and Capsomeres Induce Similar CD8+ T Cell Responses but Differ in Capacity to Induce CD4+ T Cell Responses and Antibody Responses. Frontiers in Immunology, 2020, 11, 564627.	4.8	3
22	Development and validation of serological markers for detecting recent Plasmodium vivax infection. Nature Medicine, 2020, 26, 741-749.	30.7	90
23	Immune Signature Against Plasmodium falciparum Antigens Predicts Clinical Immunity in Distinct Malaria Endemic Communities. Molecular and Cellular Proteomics, 2020, 19, 101-113.	3.8	16
24	The Association between the Comprehensive Epsteinâ€"Barr Virus Serologic Profile and Endemic Burkitt Lymphoma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 57-62.	2.5	23
25	The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Frontiers in Immunology, 2020, 11, 303.	4.8	219
26	An Analytically and Diagnostically Sensitive RNA Extraction and RT-qPCR Protocol for Peripheral Blood Mononuclear Cells. Frontiers in Immunology, 2020, 11, 402.	4.8	10
27	Validation of an Epstein-Barr Virus Antibody Risk Stratification Signature for Nasopharyngeal Carcinoma by Use of Multiplex Serology. Journal of Clinical Microbiology, 2020, 58, .	3.9	14
28	Uptake of Schistosoma mansoni extracellular vesicles by human endothelial and monocytic cell lines and impact on vascular endothelial cell gene expression. International Journal for Parasitology, 2020, 50, 685-696.	3.1	27
29	A novel population of memoryâ€activated natural killer cells associated with low parasitaemia in Plasmodium falciparumâ€exposed sickleâ€cell trait children. Clinical and Translational Immunology, 2020, 9, e1125.	3.8	7
30	Casting a Wide Net around Immunity to Malaria Catches p53. Immunity, 2019, 51, 603-605.	14.3	0
31	2018 ISV Congress: advances in the 100 years since the worldâ€™s deadliest pandemic. Human Vaccines and Immunotherapeutics, 2019, 15, 2006-2008.	3.3	0
32	Protective Immunity against Severe Malaria in Children Is Associated with a Limited Repertoire of Antibodies to Conserved PfEMP1 Variants. Cell Host and Microbe, 2019, 26, 579-590.e5.	11.0	40
33	Chimeric Murine Polyomavirus Virus-Like Particles Induce Plasmodium Antigen-Specific CD8+ T Cell and Antibody Responses. Frontiers in Cellular and Infection Microbiology, 2019, 9, 215.	3.9	11
34	Multilaboratory Assessment of Epstein-Barr Virus Serologic Assays: the Case for Standardization. Journal of Clinical Microbiology, 2019, 57, .	3.9	8
35	Human challenge models: tools to accelerate the development of malaria vaccines. Expert Review of Vaccines, 2019, 18, 241-251.	4.4	35
36	A Balanced Proinflammatory and Regulatory Cytokine Signature in Young African Children Is Associated With Lower Risk of Clinical Malaria. Clinical Infectious Diseases, 2019, 69, 820-828.	5.8	8

#	Article	IF	Citations
37	Patterns of Interindividual Variability in the Antibody Repertoire Targeting Proteins Across the Epstein-Barr Virus Proteome. Journal of Infectious Diseases, 2018, 217, 1923-1931.	4.0	13
38	Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan. Clinical Cancer Research, 2018, 24, 1305-1314.	7.0	52
39	Influence of Physicochemical Properties of Lipopeptide Adjuvants on the Immune Response: A Rationale for Engineering a Potent Vaccine. Chemistry - A European Journal, 2018, 24, 9892-9902.	3.3	9
40	Identification of Cytauxzoon felis antigens via protein microarray and assessment of expression library immunization against cytauxzoonosis. Clinical Proteomics, 2018, 15, 44.	2.1	10
41	Defined Small Molecules Produced by Himalayan Medicinal Plants Display Immunomodulatory Properties. International Journal of Molecular Sciences, 2018, 19, 3490.	4.1	19
42	Anomalies in T Cell Function Are Associated With Individuals at Risk of Mycobacterium abscessus Complex Infection. Frontiers in Immunology, 2018, 9, 1319.	4.8	18
43	High production of pro-inflammatory cytokines by maternal blood mononuclear cells is associated with reduced maternal malaria but increased cord blood infection. Malaria Journal, 2018, 17, 177.	2.3	13
44	A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1 ₄₂ in a Prime/Boost Heterologous Immunization Regimen Partially Protects Aotus Monkeys against Blood-Stage Challenge. Vaccine Journal, 2017, 24, .	3.1	16
45	Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection: CD1c ⁺ Myeloid Dendritic Cell Maturation Arrest, Induction of the Kynurenine Pathway, and Regulatory T Cell Activation. Infection and Immunity, 2017, 85, .	2.2	22
46	Recent advances in proteomic applications for schistosomiasis research: potential clinical impact. Expert Review of Proteomics, 2017, 14, 171-183.	3.0	14
47	Profiling the Targets of Protective CD8+ T Cell Responses to Infection. Molecular Therapy - Methods and Clinical Development, 2017, 7, 20-31.	4.1	7
48	Plasmacytoid dendritic cells appear inactive during sub-microscopic Plasmodium falciparum blood-stage infection, yet retain their ability to respond to TLR stimulation. Scientific Reports, 2017, 7, 2596.	3.3	24
49	Novel Plasmodium antigens identified via genome-based antibody screen induce protection associated with polyfunctional T cell responses. Scientific Reports, 2017, 7, 15053.	3.3	16
50	Polyfunctional and IFN-Î³ monofunctional human CD4+ T cell populations are molecularly distinct. JCI Insight, 2017, 2, e87499.	5.0	50
51	Dichotomous miR expression and immune responses following primary blood-stage malaria. JCI Insight, 2017, 2, .	5.0	29
52	Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity. Malaria Journal, 2016, 15, 377.	2.3	29
53	Immunomics: a 21st century approach to vaccine development for complex pathogens. Parasitology, 2016, 143, 236-244.	1.5	19
54	Mining, visualizing and comparing multidimensional biomolecular data using the Genomics Data Miner (GMine) Web-Server. Scientific Reports, 2016, 6, 38178.	3.3	22

#	Article	IF	Citations
55	Type I Interferons Regulate Immune Responses in Humans with Blood-Stage Plasmodium falciparum Infection. Cell Reports, 2016, 17, 399-412.	6.4	88
56	Chemically Attenuated Blood-Stage Plasmodium yoelii Parasites Induce Long-Lived and Strain-Transcending Protection. Infection and Immunity, 2016, 84, 2274-2288.	2.2	31
57	Specific humoral response of hosts with variable schistosomiasis susceptibility. Immunology and Cell Biology, 2016, 94, 52-65.	2.3	8
58	Defining the targets of antiparasitic compounds. Drug Discovery Today, 2016, 21, 725-739.	6.4	25
59	Antibody Signatures Reflect Different Disease Pathologies in Patients With Schistosomiasis Due toSchistosoma japonicum. Journal of Infectious Diseases, 2016, 213, 122-130.	4.0	24
60	Systems Approaches towards Molecular Profiling of Human Immunity. Trends in Immunology, 2016, 37, 53-67.	6.8	22
61	Synthesis of Mannosylated Lipopeptides with Receptor Targeting Properties. Bioconjugate Chemistry, 2016, 27, 533-548.	3.6	12
62	Profoundly Reduced CD1c ⁺ Myeloid Dendritic Cell HLA-DR and CD86 Expression and Increased Tumor Necrosis Factor Production in Experimental Human Blood-Stage Malaria Infection. Infection and Immunity, 2016, 84, 1403-1412.	2.2	22
63	Systematic evaluation of self-adjuvanting lipopeptide nano-vaccine platforms for the induction of potent CD8+T-cell responses. Nanomedicine, 2016, 11, 137-152.	3.3	12
64	Plasmodium vivax but Not Plasmodium falciparum Blood-Stage Infection in Humans Is Associated with the Expansion of a CD8+ T Cell Population with Cytotoxic Potential. PLoS Neglected Tropical Diseases, 2016, 10, e0005031.	3.0	24
65	Reduced Plasmodium Parasite Burden Associates with CD38+ CD4+ T Cells Displaying Cytolytic Potential and Impaired IFN-Î³ Production. PLoS Pathogens, 2016, 12, e1005839.	4.7	30
66	Development of a cytokine-secreting-based assay for the identification, sorting and transcriptomic analysis of polyfunctional human T cells. European Cytokine Network, 2015, 26, 67-72.	2.0	4
67	Of Monkeys and Men: Immunomic Profiling of Sera from Humans and Non-Human Primates Resistant to Schistosomiasis Reveals Novel Potential Vaccine Candidates. Frontiers in Immunology, 2015, 6, 213.	4.8	43
68	Protein Microarrays for Parasite Antigen Discovery. Methods in Molecular Biology, 2015, 1201, 221-233.	0.9	20
69	The case for a rational genome-based vaccine against malaria. Frontiers in Microbiology, 2015, 5, 741.	3.5	24
70	Large screen approaches to identify novel malaria vaccine candidates. Vaccine, 2015, 33, 7496-7505.	3.8	54
71	Synthesis and Characterisation of Selfâ€Assembled and Selfâ€Adjuvanting Asymmetric Multiâ€Epitope Lipopeptides of Ovalbumin. Chemistry - A European Journal, 2015, 21, 1251-1261.	3.3	10
72	Probing of a Human Proteome Microarray With a Recombinant Pathogen Protein Reveals a Novel Mechanism by Which Hookworms Suppress B-Cell Receptor Signaling. Journal of Infectious Diseases, 2015, 211, 416-425.	4.0	47

#	Article	IF	Citations
73	An Immunomics Approach to Schistosome Antigen Discovery: Antibody Signatures of Naturally Resistant and Chronically Infected Individuals from Endemic Areas. PLoS Pathogens, 2014, 10, e1004033.	4.7	78
74	Genome- and proteome-wide screening strategies for antigen discovery and immunogen design. Biotechnology Advances, 2014, 32, 403-414.	11.7	14
75	Genome-based vaccine design: the promise for malaria and other infectious diseases. International Journal for Parasitology, 2014, 44, 901-913.	3.1	39
76	Subcutaneous cholera toxin exposure induces potent <scp>CD</scp>103⁺ dermal dendritic cell activation and migration. European Journal of Immunology, 2013, 43, 2707-2717.	2.9	16
77	Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP). Malaria Journal, 2013, 12, 185.	2.3	30
78	Immunization with Apical Membrane Antigen 1 Confers Sterile Infection-Blocking Immunity against Plasmodium Sporozoite Challenge in a Rodent Model. Infection and Immunity, 2013, 81, 3586-3599.	2.2	18
79	DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity. PLoS ONE, 2013, 8, e55571.	2.5	127
80	A Novel Candidate Vaccine for Cytauxzoonosis Inferred from Comparative Apicomplexan Genomics. PLoS ONE, 2013, 8, e71233.	2.5	22
81	Highly Sensitive Quantitative Real-Time PCR for the Detection of Plasmodium Liver-Stage Parasite Burden following Low-Dose Sporozoite Challenge. PLoS ONE, 2013, 8, e77811.	2.5	11
82	Clinical trial in healthy malaria-naÃ¯ve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stagePlasmodium falciparumDNA vaccine combined with escalating dose human GM-CSF DNA. Human Vaccines and Immunotherapeutics, 2012, 8, 1564-1584.	3.3	44
83	Addressing the bottleneck at clinical testing of candidate malaria vaccines. Pathogens and Global Health, 2012, 106, 321-322.	2.3	1
84	Editorial. International Journal for Parasitology: Parasites and Wildlife, 2012, 1, 1.	1.5	0
85	The Role of Age and Exposure to Plasmodium falciparum in the Rate of Acquisition of Naturally Acquired Immunity: A Randomized Controlled Trial. PLoS ONE, 2012, 7, e32362.	2.5	30
86	Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses. PLoS ONE, 2012, 7, e33920.	2.5	31
87	Vaccination with Lipid Core Peptides Fails to Induce Epitope-Specific T Cell Responses but Confers Non-Specific Protective Immunity in a Malaria Model. PLoS ONE, 2012, 7, e40928.	2.5	20
88	Intermittent preventive treatment with sulfadoxine-pyrimethamine does not modify plasma cytokines and chemokines or intracellular cytokine responses to Plasmodium falciparum in Mozambican Children. BMC Immunology, 2012, 13, 5.	2.2	10
89	Sterile Protective Immunity to Malaria is Associated with a Panel of Novel P. falciparum Antigens. Molecular and Cellular Proteomics, 2011, 10, M111.007948.	3.8	134
90	Editorial. International Journal for Parasitology: Drugs and Drug Resistance, 2011, 1, 1.	3.4	0

#	Article	IF	Citations
91	Non-toxic derivatives of LT as potent adjuvants. Vaccine, 2011, 29, 1538-1544.	3.8	75
92	Toward a Surrogate Marker of Malaria Exposure: Modeling Longitudinal Antibody Measurements under Outbreak Conditions. PLoS ONE, 2011, 6, e21826.	2.5	12
93	Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults. PLoS ONE, 2011, 6, e24586.	2.5	63
94	Harnessing immune responses against Plasmodium for rational vaccine design. Trends in Parasitology, 2011, 27, 274-283.	3.3	32
95	Plasmodium immunomics. International Journal for Parasitology, 2011, 41, 3-20.	3.1	91
96	High-throughput multi-parameter flow-cytometric analysis from micro-quantities of Plasmodium-infected blood. International Journal for Parasitology, 2011, 41, 1285-1294.	3.1	26
97	Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults. Malaria Journal, 2011, 10, 168.	2.3	41
98	The Stability and Complexity of Antibody Responses to the Major Surface Antigen of Plasmodium falciparum Are Associated with Age in a Malaria Endemic Area. Molecular and Cellular Proteomics, 2011, 10, M111.008326.	3.8	78
99	Vaccinomics for the Major Blood Feeding Helminths of Humans. OMICS A Journal of Integrative Biology, 2011, 15, 567-577.	2.0	48
100	Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component. PLoS ONE, 2011, 6, e25868.	2.5	70
101	Evaluation of Approaches to Identify the Targets of Cellular Immunity on a Proteome-Wide Scale. PLoS ONE, 2011, 6, e27666.	2.5	14
102	Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein. Malaria Journal, 2010, 9, 241.	2.3	29
103	Malaria Vaccine Design: ImmunologicalÂConsiderations. Immunity, 2010, 33, 555-566.	14.3	89
104	The Australasian Contribution to Malaria Vaccine Development. Parasite Immunology, 2010, 32, no-no.	1.5	1
105	IFN-Î³ Inhibits IL-4â€“Induced Type 2 Cytokine Expression by CD8 T Cells In Vivo and Modulates the Anti-Tumor Response. Journal of Immunology, 2010, 185, 998-1004.	0.8	35
106	A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6958-6963.	7.1	412
107	Schistosomiasis vaccine discovery using immunomics. Parasites and Vectors, 2010, 3, 4.	2.5	57
108	VaxfectinÂ® enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses. Vaccine, 2010, 28, 3055-3065.	3.8	14

#	Article	IF	Citations
109	Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth. Vaccine, 2010, 28, 3201-3210.	3.8	35
110	Sterile Protection against Plasmodium knowlesi in Rhesus Monkeys from a Malaria Vaccine: Comparison of Heterologous Prime Boost Strategies. PLoS ONE, 2009, 4, e6559.	2.5	46
111	Acquired Immunity to Malaria. Clinical Microbiology Reviews, 2009, 22, 13-36.	13.6	981
112	Plasmodium: Mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity. Experimental Parasitology, 2009, 122, 112-123.	1.2	15
113	Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase (HGXPRT) in acute malaria. Malaria Journal, 2009, 8, 122.	2.3	10
114	Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics, 2008, 8, 4680-4694.	2.2	236
115	Transcriptionally active PCR for antigen identification and vaccine development: In vitro genome-wide screening and in vivo immunogenicity. Molecular and Biochemical Parasitology, 2008, 158, 32-45.	1.1	13
116	The path of discovery. Hum Vaccin, 2008, 4, 324-327.	2.4	0
117	The US Capitol Bioterrorism Anthrax Exposures: Clinical Epidemiological and Immunological Characteristics. Journal of Infectious Diseases, 2007, 195, 174-184.	4.0	36
118	Viral vectors for malaria vaccine development. Vaccine, 2007, 25, 2567-2574.	3.8	62
119	Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation. Vaccine, 2007, 25, 6635-6645.	3.8	37
120	Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization. Malaria Journal, 2007, 6, 135.	2.3	31
121	Malaria's journey through the lymph node. Nature Medicine, 2007, 13, 1023-1024.	30.7	7
122	Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines. Microbes and Infection, 2007, 9, 1439-1446.	1.9	29
123	Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines. Immunology Letters, 2007, 111, 92-102.	2.5	30
124	Vaxfectinâ„¢ enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine, 2006, 24, 1921-1927.	3.8	20
125	Identification of humoral immune responses in protein microarrays using DNA microarray data analysis techniques. Bioinformatics, 2006, 22, 1760-1766.	4.1	93
126	Induction in Humans of CD8+ and CD4+ T Cell and Antibody Responses by Sequential Immunization with Malaria DNA and Recombinant Protein. Journal of Immunology, 2004, 172, 5561-5569.	0.8	97

#	Article	IF	Citations
127	Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9952-9957.	7.1	227
128	Assessing Antigen-Specific CD8⁺ CTL Responses in Humans. , 2002, 72, 445-456.		0
129	Persistence of Protective Immunity to Malaria Induced by DNA Priming and Poxvirus Boosting: Characterization of Effector and Memory CD8+-T-Cell Populations. Infection and Immunity, 2002, 70, 3493-3499.	2.2	38
130	Protection of Humans against Malaria by Immunization with Radiationâ€AttenuatedPlasmodium falciparumSporozoites. Journal of Infectious Diseases, 2002, 185, 1155-1164.	4.0	652
131	Nucleic Acid Vaccines against Malaria. , 2002, 80, 308-321.		19
132	Determining liver stage parasite burden by real time quantitative PCR as a method for evaluating pre-erythrocytic malaria vaccine efficacy. Molecular and Biochemical Parasitology, 2001, 118, 233-245.	1.1	71
133	Expression of the chemokine MIG is a sensitive and predictive marker for antigen-specific, genetically restricted IFN-Î³ production and IFN-Î³-secreting cells. Journal of Immunological Methods, 2001, 257, 55-69.	1.4	37
134	DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. International Journal for Parasitology, 2001, 31, 753-762.	3.1	100
135	HLA degenerate T-cell epitopes from Plasmodium falciparum liver stage-specific antigen 1 (LSA-1) are highly conserved in isolates from geographically distinct areas. Parasite Immunology, 2000, 22, 469-473.	1.5	5
136	Malaria vaccinesâ€“targeting infected hepatocytes. Nature Medicine, 2000, 6, 1218-1219.	30.7	56
137	The Complexity of Protective Immunity Against Liver-Stage Malaria. Journal of Immunology, 2000, 165, 1453-1462.	0.8	313
138	HLA-DR-Promiscuous T Cell Epitopes fromPlasmodiumâ€˜falciparumPre-Erythrocytic-Stage Antigens Restricted by Multiple HLA Class II Alleles. Journal of Immunology, 2000, 165, 1123-1137.	0.8	134
139	Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine, 2000, 18, 1893-1901.	3.8	212
140	Immune effector mechanisms in malaria. Current Opinion in Immunology, 1999, 11, 412-419.	5.5	179
141	CD4⁺T-Cell- and Gamma Interferon-Dependent Protection against Murine Malaria by Immunization with Linear Synthetic Peptides from aPlasmodium yoelii17-Kilodalton Hepatocyte Erythrocyte Protein. Infection and Immunity, 1999, 67, 5604-5614.	2.2	50
142	Induction of Antigen-Specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine. Science, 1998, 282, 476-480.	12.6	761
143	Simultaneous Induction of Multiple Antigen-Specific Cytotoxic T Lymphocytes in Nonhuman Primates by Immunization with a Mixture of FourPlasmodium falciparumDNA Plasmids. Infection and Immunity, 1998, 66, 4193-4202.	2.2	62
144	Simultaneous Induction of Multiple Antigen-Specific Cytotoxic T Lymphocytes in Nonhuman Primates by Immunization with a Mixture of Four Plasmodium falciparum DNA Plasmids. Infection and Immunity, 1998, 66, 4193-4202.	2.2	20

#	Article	IF	Citations
145	Preâ€“erythrocyticâ€“stage immune effector mechanisms in Plasmodium spp. infections. Philosophical Transactions of the Royal Society B: Biological Sciences, 1997, 352, 1361-1367.	4.0	38
146	Degenerate Cytotoxic T Cell Epitopes from P. falciparum Restricted by Multiple HLA-A and HLA-B Supertype Alleles. Immunity, 1997, 7, 97-112.	14.3	190
147	Toward clinical trials of DNA vaccines against malaria. Immunology and Cell Biology, 1997, 75, 376-381.	2.3	25
148	Class I HLA-restricted cytotoxic T lymphocyte responses against malaria-elucidation on the basis of HLA peptide binding motifs. Immunologic Research, 1996, 15, 280-305.	2.9	20
149	Identification and Characterization of the Protective Gene of homolog of Exported Protein 1. Journal of Biological Chemistry, 1996, 271, 17861-17868.	3.4	81
150	Evidence for limited activation of distinct CD4+T cell subsets in response to the Plasmodium falciparum circumsporozoite protein in Papua New Guinea. Parasite Immunology, 1994, 16, 129-136.	1.5	25
151	Cytotoxic T lymphocyte (CTL) low-responsiveness to the Plasmodium falciparum circumsporozoite protein in naturally-exposed endemic populations: analysis of human CTL response to most known variants. International Immunology, 1993, 5, 37-46.	4.0	39
152	Location of human cytotoxic T cell epitopes within a polymorphic domain of the Plasmodium falciparum circumsporozoite protein. International Immunology, 1991, 3, 511-516.	4.0	60
153	Protective Immunity Against Severe Malaria is Associated with a Repertoire of Antibodies to Conserved PfEMP1 Variants. SSRN Electronic Journal, 0, , .	0.4	0